NY-FORTER
4.6.2019 15:21:12 CEST | Business Wire | Press release
Forter , the leader in e-commerce fraud prevention, today announced it has processed a record $100 billion in e-commerce transactions, a milestone no other online fraud decisioning platform has achieved to date. In turn, Forter has increased the dollar amount of processed transactions by 100 times over the past three years, and doubled the amount since January 2019 alone.
By processing massive volumes of transactions, it allows Forter to have the most comprehensive view of both consumer and fraud behavior across enterprises and industries worldwide, including luxury, travel, hospitality, on-demand services, food delivery and digital/e-commerce verticals. Merchants that are part of Forter’s global network—including well-known brands such as Nordstrom, leading online travel companies like Priceline, and fast-growing consumer start-ups such as AWAY Travel—benefit from the sheer size and varied nature of the organizations within this network.
For example, once a credit card is stolen, fraudsters attempt to use the card as much as possible over a short period of time. In order to protect against this, Forter is able to quickly leverage its massive volume of transactional data and award-winning technology to detect potential threats and block them across its global network in a split second, in essence immunizing the entire network—helping to prevent thousands of dollars in losses. Amid regulatory changes around payments and data security, such as GDPR and PSD2, Forter’s ability to detect and prevent fraud throughout the entire customer lifecycle becomes even more valuable to block various types of fraud while meeting regulatory compliance.
In another problematic scenario, users with new credit cards and/or updated address details tend to be at a greater risk of being inaccurately declined by merchants, negatively impacting the purchasing experience. With Forter’s extensive view of consumer behavior, even with updates to payment or personal information, a customer is immediately recognized as legitimate, allowing them to checkout seamlessly. It’s with this large network spanning various industries that Forter is able to protect more organizations and their customers worldwide in a faster and more accurate manner compared to any other fraud prevention provider.
“The reality is, size matters when fighting fraud. With Forter's network being five times the size of the largest global retailer, there is immense power in joining a global coalition of merchants for increased visibility, intelligence and protection, resulting in the ultimate end goal of a frictionless customer experience,” said Michael Reitblat, co-founder and CEO, Forter. “Fraud is unpredictable and chaotic, and merchants need resources to provide accuracy, adaptability and consistency, while remaining consumer-first. Top brands across the globe trust us to help them achieve it all, and today’s $100 billion milestone is a testament to that.”
Forter provides an integrated, identity-based fraud prevention platform that uses advanced machine learning technology and fraud detection capabilities. It delivers the most accurate, real-time and fully automated solution on the market today that is focused on enabling revenue and supporting business performance by solving the following challenges:
- Accuracy --accurately distinguishes legitimate buyers from fraudsters;
- Adaptability --automatically adapts to the dynamic nature of fraud and to new types of purchasing experiences customers demand (ie. BOPIS: buy online, pick-up in store);
- Consistency --delivers a consistent consumer experience from login to check-out. For example, some customers are approved when they check out with a credit card, but if they try and sign up for a loyalty program, they are denied. Consistency is critical to consumer experience.
# # #
About Forter
Forter is the leader in e-commerce fraud prevention, protecting merchants during each stage of the customer lifecycle. The company’s identity-based fraud prevention solution detects instances of fraud and abuse beyond transactions in real-time, such as attempts at account takeover and return abuse.
A team of world-class analysts constantly update Forter’s machine learning solutions with cutting-edge insights and research, ensuring the proprietary algorithms adapt to the latest fraud trends in real-time. As a result, Forter is trusted by Fortune 500 companies, online travel businesses, and fast-growing digital disrupters to deliver exceptional accuracy, a smoother user experience and elevated sales at a much lower cost.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005551/en/
Contact:
Angela Whiteford angela.whiteford@forter.com 617-620-2058
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
